[go: up one dir, main page]

WO2008006187A3 - Protein complexes for prevention and treatment of diseases with angiogenesis disorders - Google Patents

Protein complexes for prevention and treatment of diseases with angiogenesis disorders Download PDF

Info

Publication number
WO2008006187A3
WO2008006187A3 PCT/BY2007/000002 BY2007000002W WO2008006187A3 WO 2008006187 A3 WO2008006187 A3 WO 2008006187A3 BY 2007000002 W BY2007000002 W BY 2007000002W WO 2008006187 A3 WO2008006187 A3 WO 2008006187A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein complexes
treatment
diseases
angiogenic
angiogenesis disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BY2007/000002
Other languages
French (fr)
Other versions
WO2008006187A2 (en
Inventor
Aleksey M Olovnikov
Oleg N Darashkevitch
Eugeny I Goufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEGEEV YURY V
Original Assignee
LEGEEV YURY V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEGEEV YURY V filed Critical LEGEEV YURY V
Publication of WO2008006187A2 publication Critical patent/WO2008006187A2/en
Anticipated expiration legal-status Critical
Publication of WO2008006187A3 publication Critical patent/WO2008006187A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment
PCT/BY2007/000002 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders Ceased WO2008006187A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
BY20060719 2006-07-12
BYA20060719 2006-07-12
BYA20060916 2006-09-20
BY20060916 2006-09-20
BYA20061352 2006-12-28
BY20061352 2006-12-28
BYA20070027 2007-01-12
BY20070027 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008006187A2 WO2008006187A2 (en) 2008-01-17
WO2008006187A3 true WO2008006187A3 (en) 2009-02-12

Family

ID=38805594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BY2007/000002 Ceased WO2008006187A2 (en) 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders

Country Status (1)

Country Link
WO (1) WO2008006187A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100310626A1 (en) * 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
JP2012136437A (en) * 2009-04-10 2012-07-19 Fujifilm Corp Heterocyclic 5-membered ring compound
CN110105362B (en) * 2019-05-29 2020-10-23 威海中腾医药科技有限公司 Safe and green folic acid synthesis method catalyzed by heteropoly acid
EP4138831A4 (en) * 2020-04-20 2024-05-15 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOTZ HUBERT G ET AL: "Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.", JOURNAL OF GASTROINTESTINAL SURGERY, vol. 6, no. 2, March 2002 (2002-03-01), pages 159 - 166, XP002492441, ISSN: 1091-255X *
KRAUSS JÜRGEN ET AL: "Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme", BRITISH JOURNAL OF HAEMATOLOGY, vol. 128, no. 5, 1 March 2005 (2005-03-01), pages 602 - 609, XP002463022, ISSN: 0007-1048 *
RAMAKRISHNAN S ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR-TOXIN CONJUGATE SPECIFICALLY INHIBITS KDR/FLK-1-POSITIVE ENDOTHELIAL CELL PROLIFERATION IN VITRO AND ANGIOGENESIS IN VIVO", CANCER RESEARCH, vol. 56, no. 6, 1 January 1996 (1996-01-01), pages 1324 - 1330, XP001247100, ISSN: 0008-5472 *
WILD R ET AL: "INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH BY VEGF121-TOXIN CONJUGATE: DIFFERENTIAL EFFECT ON PROLIFERATING ENDOTHELIAL CELLS", BRITISH JOURNAL OF CANCER, vol. 83, no. 3, 1 January 2000 (2000-01-01), pages 1077 - 1083, XP002408273, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
WO2008006187A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
EP2896632A3 (en) Material and methods for treating or preventing HER-3 associated diseases
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2012174338A3 (en) Method of selecting therapeutic indications
ATE540709T1 (en) IMPLANTABLE MEDICAL DEVICE WITH PARTICLE COATING
EP2987807A3 (en) Antibodies recognising phospho-tau
LTPA2015052I1 (en) HUMAN MONOCLONAL ANTIBODIES TARGETED TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES SINGLE OR IN COMBINATION WITH OTHER IMMUNOTHERAPY AGENTS
WO2008060777A3 (en) Elisa for vegf
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2014183066A3 (en) Protein modification of living cells using sortase
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
EP2529224A4 (en) Sampling and testing device for the human or animal body
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
WO2011103567A3 (en) Peptides and methods for inducing cell death
EP4153042A4 (en) Systems and methods for automatic and noninvasive livestock health analysis
HK1201605A1 (en) Personalized strategic cancer treatment
EP2478901A3 (en) Neurogenic compounds
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
WO2008006187A3 (en) Protein complexes for prevention and treatment of diseases with angiogenesis disorders
EA201171232A1 (en) METHOD OF POLYPEPTIDE TRANSFER IN CELLS
WO2007028123A3 (en) Cochlear implant fitting
EP4488288A3 (en) Means and methods for aav gene therapy in humans
WO2010034514A3 (en) Cfhr1 as a c5 convertase inhibitor for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2